Three Emerging Treatments for Autism Spectrum Disorder

Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition characterised by differences in brain structure and function that affect communication, behaviour and social interaction. As research continues to clarify the biological mechanisms underlying ASD, new and innovative treatment approaches are emerging.

Below are three promising therapies currently under investigation. Each has a scientifically plausible mechanism of action, encouraging early clinical data and growing research interest. However, none are yet approved by the FDA or widely adopted in routine clinical practice.

1. Exosome Therapy for Autism

Exosomes are nano sized extracellular vesicles released by cells, including Mesenchymal Stem Cells (MSCs). They are increasingly recognised as key mediators of the therapeutic effects of MSCs, making them an attractive cell free alternative to stem cell transplantation.

In the context of autism treatment, exosomes are administered intranasally. This delivery method allows exosomes to bypass the blood brain barrier and reach the brain directly. The intranasal route is non invasive and painless, making it particularly suitable for young children with ASD.

Early clinical trials of MSC therapy using whole cells, rather than isolated exosomes, have demonstrated improvements in social interaction, language development and reductions in inflammatory markers. Importantly, no serious adverse events were reported in these early studies.

Human clinical trials investigating intranasal MSC derived exosomes specifically for Autism Spectrum Disorder are now underway. The proposed mechanisms include modulation of neuroinflammation, repair of neural circuits and effective brain delivery through blood brain barrier penetration.

While intranasal exosome therapy represents a biologically plausible and promising strategy for autism, the current evidence base remains insufficient to support routine clinical use.

2. Cerebrolysin for Autism Spectrum Disorder

There is growing interest in peptide based therapies for neurological conditions, including Autism Spectrum Disorder. Cerebrolysin is a peptide preparation designed to mimic naturally occurring neurotrophic factors, which support neuronal growth, survival and repair.

Cerebrolysin has established regulatory approval for strokes and Alzheimer’s disease in several countries, including Hong Kong. However, its use in autism remains investigational.

Limited clinical evidence suggests potential benefits for cognitive function and communication skills in children with ASD. Despite these encouraging findings, the current evidence base is not robust enough to recommend Cerebrolysin as a routine autism treatment.

One practical limitation is that Cerebrolysin must be administered via injection, which may be challenging for some children and families. It may be considered in the context of shared decision making, particularly for families who have exhausted established evidence based interventions, while larger and more rigorous clinical trials are awaited.

3. Faecal Microbiota Transplant for Autism

Faecal Microbiota Transplantation (FMT) is one of the most biologically compelling emerging interventions being studied in Autism Spectrum Disorder. Although first explored in ASD more than a decade ago, it is not yet widely available.

Research has demonstrated that many children with autism have altered gut microbiomes. Gastrointestinal symptoms are common in ASD, and when present, often respond positively to microbiome targeted interventions. Emerging evidence also suggests potential improvements in core autism symptoms, although larger randomised controlled trials are still needed.

A comprehensive review published in 2023 reported that FMT significantly reduced Autism Behaviour Checklist (ABC) scores by 14.96 points and Childhood Autism Rating Scale (CARS) scores by 6.95 points in children with Autism Spectrum Disorder. These findings are encouraging but require confirmation in larger scale studies.

In clinical practice, FMT for ASD is typically administered via capsules, tasteless liquid preparations or granules. Treatment is preceded by a bowel preparation protocol that may include antibiotics.

In Hong Kong, FMT was available privately prior to 2020 and may become available again in the future. Published paediatric studies in ASD report no serious adverse events or hospitalisations, suggesting that the treatment is generally safe when appropriately supervised.

From a functional medicine perspective, children with ASD who have significant gastrointestinal symptoms or confirmed microbiome abnormalities may represent the most rational subgroup for FMT treatment.

The Future of Biological Treatments for Autism

These three emerging therapies reinforce the understanding of Autism Spectrum Disorder as a biological condition affecting brain structure and function. As research advances and larger clinical trials are completed, we hope that exosome therapy, peptide based treatments such as Cerebrolysin, Faecal Microbiota Transplantation and other novel interventions will expand the therapeutic options available.

With continued scientific progress, children with ASD may have greater opportunities to reach their full developmental potential.

Dr Tim Trodd

Family Medicine, Functional Medicine, General Practice

MBBS (London)
DCH (London)
DRCOG (UK)
MRCGP (UK)
FHKAM (Family Medicine)

View Profile View Reports & Publications

Health Articles by Dr Tim Trodd

Interviews

Related Blogs

References

Freitag, J., Bates, D., Wickham, J., Shah, K., Huguenin, L., Tenen, A., Paterson, K. and Boyd, R. (2019) Adipose‑derived mesenchymal stem cell therapy in the treatment of knee osteoarthritis: a randomised controlled trial. Regenerative Medicine, 14(3), pp.213–230. doi:10.2217/rme-2018-0161.
Lamo‑Espinosa, J.M., Mora, G., Blanco, J.F., Granero‑Moltó, F., Núñez‑Córdoba, J.M., López‑Elío, S., Andreu, E., Sánchez‑Guijo, F., Aquerreta, J.D., Bondía, J.M., Valentí‑Azcárate, A., Del Cañizo, M.D.C., Villarón, E.M., Valentí‑Nin, J.R. and Prósper, F. (2018) Intra‑articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: long‑term follow‑up of a multicentre randomised controlled clinical trial (phase I/II). Journal of Translational Medicine, 16(1), p.213. doi:10.1186/s12967-018-1591-7.
Raman, N., Imran, S.A.M., Ahmad Amin Noordin, K.B., Wan Kamarul Zaman, W.S. and Nordin, F. (2022) Mechanotransduction of mesenchymal stem cells (MSCs) during cardiomyocytes differentiation. Heliyon, 8(11), p.e11624. doi:10.1016/j.heliyon.2022.e11624.
Song, Y., Du, H., Dai, C., Zhang, L., Li, S., Hunter, D.J., Lu, L. and Bao, C. (2018) Human adipose‑derived mesenchymal stem cells for osteoarthritis: a pilot study with long‑term follow‑up and repeated injections. Regenerative Medicine, 13(3), pp.295–307. doi:10.2217/rme-2017-0152.
Ullah, M., Liu, D.D. and Thakor, A.S. (2019) Mesenchymal stromal cell homing: mechanisms and strategies for improvement. iScience, 15, pp.421–438. doi:10.1016/j.isci.2019.05.004.
Wang, J., Xue, H., Shi, M. and Chen, R. (2026) Mesenchymal stem cell-based therapy for osteoarthritis: a systematic review and meta-analysis of clinical outcomes and functional recovery. Frontiers in Cell and Developmental Biology, 13. doi:10.3389/fcell.2025.1746471.
Zhu, C., Wu, W. and Qu, X. (2021) Mesenchymal stem cells in osteoarthritis therapy: a review. American Journal of Translational Research, 13(2), pp.448–461. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC7868850/